Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anteris Technologies Global Corp.AVR · Entity 5089 | 10% owner | January 22, 2026 | January 29, 2026 |
| MiniMed Group, Inc.MMED · Entity 3758 | 10% owner | March 05, 2026 | March 06, 2026 |
| Orchestra BioMed Holdings, Inc.OBIO · Entity 434 | 10% owner | December 31, 2023 | February 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anteris Technologies Global Corp.
Report date January 22, 2026 · Filed January 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld by Covidien Group S.a.r.l. | 15,652,173 |
Reported balance
Holding disclosure · report date 2026-01-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 15,652,173 |
MiniMed Group, Inc.
Report date March 05, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee remarks. | 252,813,348 |
Reported balance
Holding disclosure · report date 2026-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 252,813,348 |
Orchestra BioMed Holdings, Inc.
Report date December 31, 2023 · Filed February 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectHeld by Covidien Group S.a.r.l. | 5,868,916 |
Reported balance
After 2023-04-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-04-13 · Grant · Acquired 869,493 · Balance 5,868,916 F1: Represents shares acquired by a subsidiary of the reporting person, which shares were issued as an earnout under the Agreement and Plan of Merger (the "Merger Agreement") dated effective as of July 4, 2022, by and among Orchestra BioMed Holdings, Inc., Health Sciences Acquisitions Corporation 2 ("HSAC2") and HSAC Olympus Merger Sub, Inc. (as amended, the "Merger Agreement"). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired by a subsidiary of the reporting person, which shares were issued as an earnout under the Agreement and Plan of Merger (the "Merger Agreement") dated effective as of July 4, 2022, by and among Orchestra BioMed Holdings, Inc., Health Sciences Acquisitions Corporation 2 ("HSAC2") and HSAC Olympus Merger Sub, Inc. (as amended, the "Merger Agreement").
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inspire Medical Systems, Inc.
Report date May 07, 2018 · Filed May 09, 2018
Jointly reported with MEDTRONIC INC
Section 16 reporting ended · disclosed 2018-05-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 598,932 |
Reported balance
After 2018-05-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-07 · Conversion · Acquired 189,766 · Balance 598,932 F1: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. |
| Common StockSEC Table I · non-derivative | Direct | 703,866 |
Reported balance
After 2018-05-07 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-05-07 · Conversion · Acquired 104,934 · Balance 703,866 F1: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. |
| Common StockSEC Table I · non-derivative | Direct | 767,856 |
Reported balance
After 2018-05-07 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-05-07 · Conversion · Acquired 63,990 · Balance 767,856 F1: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-07 · Conversion · Disposed 1,261,949 · Balance 0 F1: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-07 · Conversion · Disposed 697,816 · Balance 0 F1: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. |
| Series F Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-05-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-07 · Conversion · Disposed 425,539 · Balance 0 F1: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2023 Filed Feb 14, 2024 23:37 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | GrantCommon Stock | 869,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-003198 · form5.xml · nonDerivative · entry 1 Medtronic plc · CIK 0001613103 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Covidien Group S.a.r.l. Disclosed balance after: 5,868,916 F1 · kind: Represents shares acquired by a subsidiary of the reporting person, which shares were issued as an earnout under the Agreement and Plan of Merger (the "Merger Agreement") dated effective as of July 4, 2022, by and among Orchestra BioMed Holdings, Inc., Health Sciences Acquisitions Corporation 2 ("HSAC2") and HSAC Olympus Merger Sub, Inc. (as amended, the "Merger Agreement"). Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:53 UTC | Orchestra BioMed Holdings, Inc. OBIO · Entity 434 | PurchaseCommon Stock | 6,835 | $9.28 | $63,435.64 |
DisclosureSEC source: 0001062993-23-001819 · form4.xml · nonDerivative · entry 1 Medtronic plc · CIK 0001613103 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Covidien Group S.a.r.l. Disclosed balance after: 4,999,423 Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:40 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries F Convertible Preferred Stock · Derivative | 425,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031845 · a4.xml · derivative · entry 6 MEDTRONIC INC · CIK 0000064670 · 10% owner Medtronic plc · CIK 0001613103 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:40 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries D Convertible Preferred Stock · Derivative | 697,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031845 · a4.xml · derivative · entry 5 MEDTRONIC INC · CIK 0000064670 · 10% owner Medtronic plc · CIK 0001613103 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,934 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:40 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,261,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031845 · a4.xml · derivative · entry 4 MEDTRONIC INC · CIK 0000064670 · 10% owner Medtronic plc · CIK 0001613103 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189,766 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.exercise_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. F1 · derivative.expiration_date: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:40 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 63,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031845 · a4.xml · nonDerivative · entry 3 MEDTRONIC INC · CIK 0000064670 · 10% owner Medtronic plc · CIK 0001613103 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 767,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:40 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 104,934 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031845 · a4.xml · nonDerivative · entry 2 MEDTRONIC INC · CIK 0000064670 · 10% owner Medtronic plc · CIK 0001613103 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:40 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | ConversionCommon Stock | 189,766 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-031845 · a4.xml · nonDerivative · entry 1 MEDTRONIC INC · CIK 0000064670 · 10% owner Medtronic plc · CIK 0001613103 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 598,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series C, Series D and Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's initial public offering for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation, as amended). These shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.